Signal Genetics Inc (SGNL)

[KoenigSalomon]

Signal Genetics Announces Master Service Agreement
CARLSBAD, Calif., June 30, 2015 (GLOBE NEWSWIRE) -- Signal Genetics, Inc. (NASDAQ:SGNL) (Signal), a commercial stage, molecular genetics diagnostic company focused on providing innovative diagnostic services that help physicians make better-informed decisions concerning the care of their patients suffering from cancer, today announced the signing of a Master Service Agreement (MSA) with a leading pharmaceutical company. Under the MSA, Signal's proprietary MyPRS® genetic test will be run across multiple clinical trials in connection with the development of novel treatments for patients with multiple myeloma.

Signal and the pharmaceutical company have triggered the first of four studies as part of the MSA. Under the agreement, MyPRS® will help inform patterns of response to novel therapy regimens with the aim of enabling physicians to better manage multiple myeloma patients based on their specific genetic profile.

Michael Cerio, SVP of Commercial Strategy and Business Development, commented, "This services agreement with a leading pharmaceutical company is a significant achievement for Signal, and validates the potential of our technology to impact therapy decisions in multiple myeloma. We believe this agreement demonstrates that the pharmaceutical industry recognizes the value of MyPRS® as part of the genetic testing armament in cancer. Developing a pipeline of pharmaceutical company relationships is a key objective for Signal, and we plan to pursue additional clinical trial service agreements with multiple clients as part of our overarching commercial strategy going forward."